CYTK Earnings & Financial Statements
Cytokinetics, Incorporated
$65.03
+$1.60(+2.52%)
33
Overall
40
Value
18
Tech
42
Quality
Market Cap
$8.82B
Volume
162.88K
52W Range
$54.30 - $88.31
Target Price
$108.38
CYTK earnings and financial statements: Cytokinetics, Incorporated's income statement, balance sheet and cash flow statement, annual and quarterly.
CYTK Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $88.04M | $18.47M | $7.53M | $94.59M | $70.43M |
| Cost of revenue | $416.03M | $339.41M | $330.12M | $240.81M | $159.94M |
| Operating income | -$612.26M | -$536.25M | -$496.20M | -$324.20M | -$186.31M |
| EBITDA | -$729.25M | -$542.29M | -$486.05M | -$336.69M | -$183.71M |
| Net income | -$784.96M | -$589.53M | -$526.24M | -$388.95M | -$215.31M |
| EPS (diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.42B | $1.40B | $824.32M | $1.01B | $841.32M |
| Total liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597.46M |
| Shareholders’ equity | -$659.63M | -$135.37M | -$386.32M | -$107.90M | $243.86M |
| Cash and equivalents | $122.52M | $94.86M | $113.02M | $65.58M | $112.67M |
| Long-term debt | $354.35M | $205.81M | $178.81M | $190.71M | $159.60M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$510.01M | -$395.89M | -$414.33M | -$299.52M | -$142.52M |
| Capital expenditure | -$24.81M | -$3.91M | -$1.42M | -$11.34M | -$48.87M |
| Free cash flow | -$534.82M | -$399.80M | -$415.75M | -$310.85M | -$191.39M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CYTK | $65.03 | +2.5% | 162.88K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cytokinetics, Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW